Sanjivani Paranteral FY26: A ₹6 Crore March Ships Nothing, and the Full Year Pays for It

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1 — At a Glance

Sanjivani Paranteral closed FY26 with consolidated revenue of ₹68.67 crore, down from ₹70.10 crore the year before — a 2% dip that reads mild until you find the crater it’s smoothing over. The March 2026 quarter did the damage: sales of ₹13.21 crore against ₹18.18 crore a year earlier, and net profit of ₹0.55 crore versus ₹2.19 crore — a 74.9% fall. Full-year PAT landed at ₹6.69 crore, down 17.3%.

The company itself points to a specific cause: no exports left the building in March, stranded by trade-route disruption. For an outfit that ships roughly 78.5% of revenue abroad, an export freeze in the final month is not a rounding error — it’s the whole quarter.

Underneath sits a business that spent the year adding plants faster than sales. Borrowings tripled to ₹14.28 crore, fixed assets more than doubled to ₹48.49 crore, and the market pays 28.4x earnings for the result. The question the year poses: how much of tomorrow was bought with today’s balance sheet?

2 — Introduction

Incorporated in 1994, Sanjivani Paranteral is a research-based, export-oriented pharmaceutical maker — WHO-GMP, DIGEMID and DDA certified, working across parenteral (injectable) and oral solid formulations. It runs plants at Navi Mumbai and Dehradun, sells into roughly 25 countries, and leans heavily on Middle East & Africa, Latin America and CIS markets.

FY26 was the year the company tried to stop being one thing. Management described the shift from a single-engine formulations business toward three verticals: base formulations, a new IV-fluids plant in Pune under subsidiary SPL Infusion, and a nutraceutical arrangement in Prague through Alevia Healthcare. The Pune facility commenced commercial production during the year; the Prague plant recorded initial shipments of about USD 0.5 million.

The corporate calendar was busy in other ways too. In September 2025, shareholders re-appointed Ashwani Khemka as Managing Director for a five-year term to July 2030, and appointed HD and Associates as secretarial auditor. In May 2026, the board approved a valuer’s appointment for a proposed warrant issue on a preferential basis — the company reaching, once again, for fresh capital.

3 — Business Model: WTF Do They Even Do?

They make injectables and pills, and they mostly sell them somewhere else. Injectables contributed 53.45% of FY26 revenue, tablets 43.10%, and nutraceuticals a rounding-error 3.45%. The therapeutic spread is almost comically wide — CNS, CVS, antibiotics, urology, anaesthetics, anti-diabetics, anti-fungals, anti-depressants, muscle relaxants, vitamins — the kind of portfolio that reads less like a focused strategy and more like a pharmacy that never said no to a customer.

The real story is geography. Exports were 78.5% of FY26 revenue, with core markets — CIS, Middle East & Africa, Latin America — accounting for around 77%. That export tilt is the entire pitch: a small Indian manufacturer with WHO-GMP certification selling into markets that value the certificate. It is also the entire vulnerability, as March 2026 demonstrated when the trade routes closed and the revenue simply didn’t ship.

The newer engines are still warming up. The Pune IV-fluids plant lifted from about ₹1.2 crore of quarterly revenue in Q3 to ₹2.7 crore in Q4 (management commentary) — real, but tiny against the group. The Prague nutraceutical arrangement, at 45% ownership, contributes profit rather than consolidated revenue, and management noted no profit was booked in FY26 due to first-year dividend restrictions. Two growth stories, both currently more slide than statement.

Reader question: when a company runs one plant that pays the bills and two that promise to, which one deserves your attention first?

4 — Financials Overview

Figures are consolidated, in ₹ crore.

The quarter fell off a cliff on every line — revenue down 27% YoY and 40% QoQ, operating profit and PAT down more. Operating margin compressed to 11.88% from 14.36% a year earlier, the figure sitting on the data sheet.

From the